We confirmed the significant enrichment for ESR1 mutations in metastatic tumors (18.3% in metastases vs. 2.2% in local disease, p<3e-80; Fig 2A, S3 Table, S5–S7 Tables). Here, ESR1 is linked to metastatic neoplasm.